A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant therapy in the treatment of patients with dermatomyositis
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Begelomab (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Acronyms ADN016
- Sponsors ADIENNE
Most Recent Events
- 14 Mar 2022 New trial record